Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 6Phase 1/2 4Phase NA 1Phase 2/3 1

Status

Completed 8Unknown 7Recruiting 4Suspended 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3NET 1Endocrine 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × S 1 (combination) × Clear all
NCT06732856 2025-07-28

NEO-CLAUD

Asan Medical Center

Phase 1/2 Recruiting
57 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07025889 2025-06-18

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Ruijin Hospital

Phase 1/2 Recruiting
55 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Chinese PLA General Hospital

Phase 1/2 Recruiting
90 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06038461 2024-10-01

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
40 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡